StreetAlpha
13F holdings · Q3 2026

Bvf Inc/il

San Francisco, CA · files as Bvf Inc/il
Know the moment Bvf Inc/il filesYou follow Bvf Inc/il An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1056807

Bvf Inc/il reported 47 stocks worth $3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (16.6%), KYMR (14.2%) and GHRS (6.7%). Compared with Q2 2026, the fund opened new positions in PYXS, ALEC and TCGX, added to ALKS, STOK and TYRA and trimmed RVMD, XNCR and NKTR.

Latest filing: what Bvf Inc/il did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new7 added15 trimmed1 sold outBought about $234M · sold about $660M
New 4
Added 7
See all 7 →
Trimmed 15
See all 15 →
Sold out 1
  • Xoma Royalty Corpo$323M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$3B−22.3% vs last quarter
Stocks held474 new · 1 sold out
Top 5 weight48.8%fairly concentrated
Turnover29%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$505M16.6%2.5M−505K (−17%)8 of 8
2
KYMR
Kymera Therapeutics Inc
$433M14.2%3.9MNo change8 of 8
3
GHRS
GH Research PLC
$203M6.7%8.7MNo change8 of 8
4
MLTX
Moonlake Immunotherapeutics
$187M6.2%16MNo change8 of 8
5
XNCR
Xencor Inc
$155M5.1%6.2M−907K (−13%)8 of 8
6
NKTR
Nektar Therapeutics
$129M4.3%2.1M−257K (−11%)5 of 8
7
ALKS
Alkermes PLC
$115M3.8%2.8M+692K (+32%)3 of 8
8
STOK
Stoke Therapeutics Inc
$93.8M3.1%3.6M+1.1M (+42%)5 of 8
9
TYRA
Tyra Biosciences Inc
$92.2M3.0%4.2M+2.7M (+186%)8 of 8
10
ZYME
Zymeworks Inc
$91.8M3.0%3.5M−185K (−5%)8 of 8
🔒 37 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
XOMA ROYALTY CORPORATION
$323M7.6M

Reported value

last 8 quarters
$3BQ4 '24
$2.5BQ1 '25
$2.8BQ2 '25
$2.5BQ3 '25
$3BQ4 '25
$3.1BQ1 '26
$3.9BQ2 '26
$3BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Bvf Inc/il 13F FAQ

What does Bvf Inc/il own?

Bvf Inc/il reported 47 stocks worth $3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (16.6%), KYMR (14.2%) and GHRS (6.7%). The table above lists every position in the filing (the top 10 without an account).

What did Bvf Inc/il buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 7 added to, 15 trimmed and 1 sold out. New positions include PYXS, ALEC and TCGX.

When will Bvf Inc/il file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Bvf Inc/il's portfolio worth?

The Q3 2026 filing reports $3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.